Advanced glycation end products (AGEs) activate mast cells

E Sick¹,², S Brehin¹,², P André¹,², G Coupin¹,², Y Landry¹,², K Takeda¹,² and JP Gies¹,²

¹Université de Strasbourg, Faculté de Pharmacie, Illkirch, France, and
²CNRS, UMR 7213, Laboratoire de Biophotonique et Pharmacologie, Illkirch, France

BACKGROUND AND PURPOSE
Advanced glycation endproducts (AGEs) represent one of the many types of chemical modifications that occur with age in long-lived proteins. AGEs also accumulate in pathologies such as diabetes, cardiovascular diseases, neurodegeneration and cancer. Mast cells are major effectors of acute inflammatory responses that also contribute to the progression of chronic diseases. Here we investigated interactions between AGEs and mast cells.

EXPERIMENTAL APPROACHES
Histamine secretion from AGEs-stimulated mast cells was measured. Involvement of a receptor for AGEs, RAGE, was assessed by PCR, immunostaining and use of inhibitors of RAGE. Production of reactive oxygen species (ROS) and cytokines was measured.

KEY RESULTS
Advanced glycation endproducts dose-dependently induced mast cell exocytosis with maximal effects being obtained within 20 s. RAGE mRNA was detected and intact cells were immunostained by a specific anti-RAGE monoclonal antibody. AGEs-induced exocytosis was inhibited by an anti-RAGE antibody and by low molecular weight heparin, a known RAGE antagonist. RAGE expression levels were unaltered after 3 h treatment with AGEs. AGE-RAGE signalling in mast cells involves Pertussis toxin-sensitive G- proteins and intracellular Ca²⁺ increases as pretreatment with Pertussis toxin, caffeine, 2-APB and BAPTA-AM inhibited AGE-induced exocytosis. AGEs also rapidly stimulated ROS production. After 6 h treatment with AGEs, the pattern of cytokine secretion was unaltered compared with controls.

CONCLUSIONS AND IMPLICATIONS
Advanced glycation endproducts activated mast cells and may contribute to a vicious cycle involving generation of ROS, increased formation of AGEs, activation of RAGE and to the increased low-grade inflammation typical of chronic diseases.

Abbreviations
2-APB, 2-aminoethoxydiphenyl borate; AGEs, advanced glycation endproducts; Gal-BSA, galactosamide-bovine serum albumin adduct; Glu-BSA, glucosamide-BSA; Lact-BSA, lactosyl-BSA; LMWH, low molecular weight heparin; mAb, monoclonal antibody; Man-BSA, p-aminophenylmannopyranoside-BSA; Malt-BSA, maltosyl-BSA; PTX, Pertussis toxin; RAGE, receptor for AGES; ROS, reactive oxygen species

Introduction
Advanced glycation endproducts (AGEs) form a heterogeneous group of irreversible adducts resulting from non-enzymatic glycation and oxidation of proteins (Baynes, 2001). Reducing sugars such as glucose, react non-enzymatically with amino groups of proteins, lipids and nucleic acids to produce AGEs via the Maillard reaction that involves a series of reactions forming Schiff bases and Amadori products (Singh et al., 2001). AGEs accumulate in diverse pathological conditions including hyperglycaemia.
and diabetes (Brownlee, 1992), amyloidosis (Yan et al., 1996), tumours (Taguchi et al., 2000), diabetic vascular dysfunction (Park et al., 1998) and cardiac diastolic dysfunction (Li et al., 2005), oxidant stress and inflammation (Ramasamy et al., 2005). It has also been suggested that AGES form during natural aging, in particular as a consequence of exposure of long-lived proteins to homeostatic levels of glucose. The development of increased insulin resistance in the aging population is also believed to favour generation of AGES (Ramasamy et al., 2005).

Many receptors for AGES have been identified, including scavenger receptors SR-A type I and type II, SR-BI, CD36 (Oghami et al., 2002), galectin-3 and RAGE (Neeper et al., 1992; Schmidt et al., 1992; El Khoury et al., 1994; Vlassara et al., 1995; Li et al., 1996). Such receptors have been linked to a number of different functions including detoxification/removal of AGES and modulation of gene expression by activation of receptor-triggered signal transduction pathways (Hudson et al., 2003). Among these AGE-binding proteins, RAGE has been clearly identified as a signal transduction receptor. RAGE belongs to the immunoglobulin superfamily of receptors and is a multiligand receptor. In addition to AGES, RAGE is also a receptor for amphoterin (Hori et al., 1995), S100/calgranulins (Hofmann et al., 1999), amyloid-β peptide and β-sheet fibrils (Yan et al., 1996). The AGE-RAGE interaction was shown to activate the NF-κB pathway (Schmidt et al., 2001). NF-κB is a critical transcription factor transducing a variety of inflammatory and pro- or anti-apoptotic signals in the cell, depending on the time course, site and chronicity of stimulus. Importantly, one consequence of RAGE-dependent activation of NF-κB is the up-regulation of RAGE itself (Li and Schmidt, 1997). Thus, the AGE-RAGE system is likely to sustain the chronic inflammatory state that characterizes many AGE-related pathologies (Schmidt et al., 2001).

Chronic inflammation is a major causative factor in a wide range of human pathologies such as cardiovascular diseases, neurodegeneration and cancer. An increased number of mast cells at sites of chronic inflammation was first described over a hundred years ago (Ehrlich, 1879). Mast cells are tissue dwelling cells that play a pivotal role in allergic reactions and take part in other pathophysiological conditions such as innate and acquired immunity, autoimmune diseases, wound healing, fibrosis and tumours (Gurish and Austen, 2001; Bischoff, 2007). Activated mast cells release stored and de novo synthesized mediators including histamine, cytokines, leukotrienes, prostaglandins and proteases (Marshall, 2004). Mast cell degranulation can thus initiate an acute inflammatory response that might contribute to the progression of chronic diseases. Mast cells could therefore represent a major actor in the low-grade chronic inflammatory state observed in pathologies characterized by a strong accumulation of AGES. However, to date, the involvement of mast cells in diabetes, cardiovascular diseases, neurodegeneration or cancers is poorly studied.

We thus investigated the possible stimulatory effects of AGES on mast cells. Here, we show for the first time that AGES rapidly induce secretion of histamine from rat peritoneal mast cells. Pretreatment with an anti-RAGE monoclonal antibody (mAb) and with low molecular weight heparin, an antagonist of RAGE, inhibits AGE-induced degranulation. Pretreatment with Pertussis toxin also inhibited AGE-stimulated secretion, consistent with RAGE signalling involving G-proteins. RAGE-mediated exocytosis required the mobilization of intracellular calcium pools. We also found that AGES stimulated the production of reactive oxygen species (ROS) in mast cells. Taken together, our results indicate that mast cells may play a key role in AGE-mediated inflammatory processes.

**Methods**

**Isolation and purification of mast cells**

All animal care and experimental procedures were in accordance with Institutional policies (N° D-67-218-26, Direction Départementale des Services Vétérinaires du Bas-Rhin). Mature mast cells were isolated as previously described (Ferry et al., 2001). Briefly, male Wistar rats (250–350 g, 12–14 weeks old), raised in the animal house facilities in the Faculty of Pharmacy, were anesthetized with sodium pentobarbital (50 mg·kg⁻¹ ip), before exsanguination. Buffer (10 mL of 137 mM NaCl, 2.7 mM KCl, 0.3 mM CaCl₂, 1.0 mM MgCl₂, 0.4 mM NaH₂PO₄, 5.6 mM glucose, 10 mM HEPES and NaOH to pH 7.4) supplemented with 0.1% BSA was injected i.p. Peritoneal fluid was collected after gentle abdominal massage and centrifuged for 3 min at 180 × g. The pellet of mixed peritoneal cells was resuspended in the same buffer and mast cells were purified by centrifugation for 10 min at 220 × g on a discontinuous BSA gradient (30% and 40%, w/v). The approximate yield of mast cells was 1–1.5 × 10⁶ cells per animal. The pellet was then resuspended and mast cells were examined under a light microscope for viability (>95%) and purity (>97%) using Trypan blue and toluidine blue respectively.

**RNA extraction and RT-PCR**

Total RNA was extracted from mast cells with PureZOL™ reagent (Bio-Rad, Hercules, CA, USA).
according to the manufacturer’s recommendations. Reverse transcription (RT) was performed using 500 ng total RNA with the SuperScript™III First-strand synthesis system (Invitrogen, Paisley, UK) according to the manufacturer’s protocol. Amplification was assessed using 1 μL RT products in a mixture containing 200 μM of each dNTP, 0.5 μM oligonucleotide primer, 1 × Phusion HF buffer and 0.02 U·μL⁻¹ Phusion DNA polymerase (Finnzymes, Espoo, Finland). PCR primers 5′-GAATTTGTCG ATGAGGGAC-3′ (forward) and 5′-CAACAGCTGA ATGCCCTCTG-3′ (reverse) were used to detect rat RAGE mRNA [25], and 5′-ATGACACAGTCC ATGGCAT-3′ (forward) and 5′-TTCAAGTCTGGG ATGACCTT-3′ (reverse) were used to detect rat GAPDH mRNA.

**Immunofluorescence microscopy**

Purified mast cells were allowed to adhere to glass coverslips for 1 h at 37°C. Cells were fixed for 10 min at −20°C with 100% methanol. Non-specific binding sites were blocked with 2% BSA/PBS for 1 h at room temperature under gentle agitation. Mast cells were incubated with a primary monoclonal antibody (mAb) directed against RAGE (10 μg·mL⁻¹) for 1 h at room temperature under gentle agitation. This mAb targets an extracellular epitope of RAGE, as it blocks AGE binding to RAGE. Mast cells were then incubated for 1 h at room temperature with the secondary Ab (FITC-coupled rabbit anti-goat IgG, 1 μg·mL⁻¹) under gentle agitation. Coverslips were mounted and observed using an epifluorescence microscope (Nikon Diaphot). As control, no fluorescence was observed from cells treated only with the secondary FITC-coupled Ab.

**Quantification of mast cell exocytosis**

Purified mast cells (2.5 × 10⁴ cells/assay) were preincubated for 5 min at 37°C before challenge with different agents for 10 min at 37°C. Reactions were stopped by adding ice-cold buffer. Exocytosis of mast cells was quantified by determining the amount of secreted histamine by spectrofluorimetry, as previously described (Ferry et al., 2001; Sick et al., 2009). Values for stimulated histamine release in the supernatant were expressed as a percentage of the total cellular histamine content obtained after cell lysis (supernatant/(supernatant + pellet) × 100) and were corrected for the basal release of histamine (similarly calculated) that occurred in the absence of any stimulus. Basal histamine release from control non-stimulated cells was less than 5% of total content.

**Measurement of intracellular calcium**

Intracellular Ca²⁺ was measured from Fura-2-loaded mast cell suspensions using a spectrofluorimeter (Hitachi F-2000) essentially as previously described (Kassel et al., 1995). Briefly, mast cells (1 × 10⁶ cells·mL⁻¹) were incubated with 1 μM Fura-2/AM for 15 min at room temperature in HEPES buffer. Cells were then washed twice in HEPES buffer and re-suspended in the same buffer at 1 × 10⁶ cells·mL⁻¹ in a 1 cm quartz cuvette. Cells were continuously stirred and sequentially excited at 340 and 380 nm for 1 s periods at room temperature; emitted fluorescence was measured at 510 nm (Lynch et al., 1994).

**Assay of cytokine secretion**

Mast cells (5 × 10⁶ cells·mL⁻¹) were challenged with the AGE mimetic, glucosamide-bovine serum albumin (Glu-BSA) (10 μM), peptide 4N1 (100 μM) or compound 48/80 (1 μg·mL⁻¹) and incubated for 6 h at 37°C. After centrifugation, the supernatant was incubated overnight at 4°C on a membrane array coated with immobilized, capture anti-cytokine mAbs (RayBio® Rat Cytokine Antibody Array, RayBiotech, Norcross, GA, USA). Determination and quantification of cytokines were done according to the manufacturer’s instructions.

**Determination of reactive oxygen species (ROS)**

Mast cells (10⁶·mL⁻¹) were preincubated for 5 min at 37°C. In total, 10 μL aliquots were stimulated with 10 μM Glu-BSA for 5 min. ROS were immediately determined by a chemiluminescent assay as previously described (André et al., 2005).

**Data analysis**

Results are presented as mean ± SEM. from at least three independent experiments. Data were analysed with one-way ANOVA (followed by Bonferroni’s post hoc test when appropriate). Significant differences between means were assumed when P < 0.05.
anti-goat IgG were from Sigma (St. Louis, MO, USA). Peptide 4N1 was from Bachem (Bubendorf, Switzerland). Anti-RAGE mAb was from R&D Systems (Minneapolis, MN, USA) and anti-CD48 mAb (clone OX45) was from Serotec (Oxford, UK).

**Results**

**AGEs induce rapid mast cell exocytosis**

A number of prototype AGEs were tested for their capacity to activate mast cell exocytosis. Glu-BSA is a compound widely used to mimic AGEs (Li et al., 1996; Kuniyasu et al., 2003; Mercer et al., 2004; Valencia et al., 2004; Ishiguro et al., 2005) and Gal-BSA has also been used in some studies (Wang et al., 2002). We found that stimulation of rat isolated peritoneal mast cells by Glu-BSA, Man-BSA and Gal-BSA induced exocytosis in a dose-dependent manner, as quantified by secreted histamine. A maximal effect of 65–75% release of total histamine content was reached at 10 μM with an EC50 close to 1 μM (Figure 1A). In contrast, Lact-BSA and Malt-BSA were without effect. The kinetics of exocytosis induced by Glu-BSA were rapid, with maximal effects being obtained within 20 s (Figure 1B).

In order to verify that the stimulatory effects of AGEs were not of cytotoxic nature (e.g. non-specific cell lysis), mast cells were incubated in the presence of two metabolic inhibitors (2,4-dinitrophenol, deoxyglucose). This treatment has been long ago shown to inhibit increases in Ca2+ uptake and exocytotic responses from mast cells stimulated by IgE or compound 48/80 (Cochrane and Distel, 1982; Mohr and Fewtrell, 1990) but not by the Ca2+ ionophore A23187 (Cochrane and Distel, 1982). As shown in Figure 1C, pre-incubation of mast cells with metabolic inhibitors resulted in a significant decrease in exocytosis induced by Glu-BSA, Man-BSA and Gal-BSA. This indicates that AGE-induced exocytosis from mast cells does not result from a non-specific increase in Ca2+ subsequent for example to lysis of cell membranes. Cell viability was also assessed by Trypan blue staining, with the percentage of living mast cells after Glu-BSA treatment being similar to that observed in resting mast cells, both of them being greater than 96% (Figure 1D). This confirmed that...
AGE-induced exocytosis did not arise from cytotoxicity.

**Role of RAGE in AGE-induced mast cell activation**

To our knowledge, the presence of RAGE in rat peritoneal mast cells has never been previously described. Therefore, we first checked the expression of RAGE in mast cells by using specific PCR primers for the detection of RAGE mRNA (Figure 2A). A PCR product of 453 bp in size was found, as expected for rat RAGE (Sorci *et al.*, 2003). RAGE expression on fixed, intact rat peritoneal mast cells was also assessed by immunostaining using a specific anti-RAGE mAb that targets an extracellular epitope on RAGE and standard epifluorescence microscopy. The observed pattern of staining is consistent with RAGE being expressed at the cell membrane (Figure 2B). According to the manufacturer, 5–25 μg·mL⁻¹ of this function-blocking mAb blocks 50% of the binding of AGE-BSA to RAGE, with ≥95% inhibition of binding being achieved at a concentration of 166 μg·mL⁻¹. Thus, the effects of this anti-RAGE mAb were tested at 10 and 100 μg·mL⁻¹. Glu-BSA-induced exocytosis was dose-dependently inhibited by anti-RAGE mAb (40% inhibition at 10 μg·mL⁻¹ and 60% inhibition at 100 μg·mL⁻¹; Figure 2C). Pretreatment with an isotype control IgG (10 and 100 μg·mL⁻¹ anti-CD48 Ab OX45) was without effect on Glu-BSA-induced exocytosis (Figure 2C), consistent with a lack of non-specific action of the anti-RAGE mAb. Basal exocytosis from cells in the absence of Glu-BSA was unaffected by pretreatment with 100 μg·mL⁻¹ anti-RAGE mAb (data not shown). Low molecular weight heparin (LMWH), an antagonist of RAGE (Myint *et al.*, 2006), was also tested. Mast cell exocytosis was dose-dependently inhibited by LMWH (Figure 2D). The maximal inhibitory effect against Glu-BSA-induced exocytosis obtained after pre-incubation with LMWH (5 IU·mL⁻¹) was greater than 75%.

**Signalling pathway for AGE-induced exocytosis**

A few previous studies have addressed the downstream signalling pathways consequent to RAGE

![Figure 2](image-url)  
Receptor for advanced glycation endproduct (RAGE) expression in rat peritoneal mast cells. mRNA for RAGE was detected by first strand cDNA PCR (A). Immunocytochemical determination of RAGE on intact, fixed mast cells (B). Effect of pretreatment with anti-RAGE mAb on exocytosis induced by Glu-BSA (C). Cells were pre-incubated with anti-RAGE mAb (1 h, 37°C) and then stimulated with 10 μM Glu-BSA for 10 min at 37°C. Pretreatment with an isotype control IgG (10 and 100 μg·mL⁻¹ anti-CD48 Ab OX45) was without effect on Glu-BSA secretory responses. Data are mean ± SEM for three independent experiments. ***p < 0.001, significantly different compared with untreated cells. Effect of pretreatment with low molecular weight heparin (LMWH) on exocytosis induced by Glu-BSA (D). Cells were pre-incubated with LMWH (5 min, 37°C) and then stimulated for 10 min with 1 μM Glu-BSA at 37°C. Data are mean ± SEM from three independent experiments. Effect of pretreatment with *Pertussis* toxin (PTX) on exocytosis induced by AGEs (E). Cells were pre-incubated with PTX (20 ng·mL⁻¹, 2 h, 37°C) and then stimulated for 10 min at 37°C with three different AGEs, all at 10 μM. Data are mean ± SEM for three independent experiments. ***p < 0.001, significantly different compared with the absence of PTX. AGEs, advanced glycation endproducts.
activation. For example, engagement of RAGE has been shown to trigger p21ras, p44/p42 MAP kinases, p38 MAP kinases, rho GTPases, PI3K and the JAK/STAT pathway, leading to downstream consequences such as the activation of NF-κB and CREB (Yan et al., 2003). Other reports have suggested a possible coupling of RAGE with a pertussis toxin-sensitive G-protein (Degryse et al., 2001; Yang et al., 2007). In addition to the classical activation pathway involving high affinity IgE receptor FceRI binding, mast cells are also activated by a G_{i}-protein dependent pathway (Aridor et al., 1993; Ferry et al., 2002). We therefore assessed the possible involvement of G-proteins following stimulation of RAGE by AGES. As illustrated in Figure 2E, pre-incubation of mast cells with Pertussis toxin resulted in a significant decrease in exocytosis induced by Glu-BSA, Man-BSA and Gal-BSA. These results support the implication of G-proteins in downstream RAGE signalling, in agreement with previously published reports (Degryse et al., 2001; Yang et al., 2007).

Mast cell exocytosis requires an increase in intracellular Ca^{2+} (Nakamura and Ui, 1985; Mousli et al., 1989; Bueb et al., 1992; Ferry et al., 2001). In order to determine whether AGE-induced histamine secretion was Ca^{2+}-dependent, mast cells were loaded with Fura-2 and stimulated with 10 μM Glu-BSA. As illustrated in Figure 3A, application of Glu-BSA induced a rapid increase in intracellular Ca^{2+}. In contrast, Lact-BSA was without effect on intracellular Ca^{2+}, consistent with the absence of histamine secretion after pretreatment with this AGE prototype (Figure 3B). To confirm that a rise in intracellular Ca^{2+} was necessary for AGE-induced secretion, mast cells were pretreated with BAPTA-AM (Gianonnie et al., 2004). The resulting dose-dependent chelation of intracellular Ca^{2+} was mirrored by a similar inhibition of Glu-BSA stimulated secretion of histamine (Figure 3C). As increase in intracellular Ca^{2+} can either result from an external influx and/or release from internal Ca^{2+} stores, histamine secretion induced by Glu-BSA was measured in Ca^{2+}-free buffer (Figure 3D). Histamine secretion induced by Glu-BSA in Ca^{2+}-free buffer was similar to that obtained in Ca^{2+}-containing HEPES buffer. These data indicate that Glu-BSA-induced exocytosis is exclusively dependent from internal calcium stores. In order to confirm this observation, mast cells were pretreated with caffeine and 2-APB, compounds that interfere with release of Ca^{2+} from internal stores by acting as antagonists of the inositol trisphosphate receptor (IP_{3}; Maruyama et al., 1997; Teraoka et al., 1997). Both caffeine and 2-APB produced inhibition of Glu-BSA induced secretion in a dose-dependent manner (Figures 3E, F). Although 2-APB has more recently been described to inhibit Ca^{2+} influx through transient receptor potential (TRP) channels (Togashi et al., 2008), the observed Glu-BSA induced secretion in the absence of extracellular Ca^{2+} is consistent with the inhibitory effect of 2-APB arising from its action on Ca^{2+} release from internal stores.

**AGEs induce ROS production in mast cells**

Because reactive oxygen species (ROS) strongly sustain both inflammatory reactions and generation of AGES (Ramasamy et al., 2005), we determined whether Glu-BSA was capable of increasing ROS production in mast cells. As shown in Figure 4A, we found using a chemiluminescent assay that Glu-BSA dose-dependently increased ROS production in mast cells, with a fourfold increase being obtained at 10 μM Glu-BSA. The kinetics of ROS production induced by Glu-BSA were rapid, with maximal effects being obtained within 30 s (Figure 4B). Pretreatment with a function blocking anti-RAGE mAb significantly inhibited ROS production stimulated by Glu-BSA, with measured levels of ROS being not different from those produced by control, untreated, cells (Figure 4C). These data are consistent with RAGE being the receptor responsible for AGE-stimulated ROS production in mast cells.

**Cytokine secretion and RAGE expression are unchanged in AGE-stimulated mast cells**

Several studies have suggested that ligand-RAGE interactions in endothelial cells, smooth muscle cells, monocytes/macrophages and neurons result in activation of the NF-κB pathway, thereby inducing the subsequent secretion of TNF-α, IL-6 or IL-1β (Ramasamy et al., 2005). We therefore assessed whether cytokine secretion from mast cells was increased following stimulation by Glu-BSA. Using an array assay for 19 different cytokines, no significant differences were found between the level of cytokines secreted basally from non-stimulated mast cells and the level of cytokines secreted after 6 h pretreatment with 10 μM Glu-BSA (Figure 5A). We also tested for cytokine secretion induced by compound 48/80 (1 μg.mL^{-1}; Figure 5B) and peptide 4N1 (100 μM; Figure 5C), two other non IgE-related compounds known to cause histamine release (Mousli et al., 1989; Miller et al., 1995; Sick et al., 2009). No significant differences were found between the level of cytokines secreted basally from non-stimulated mast cells and the level of cytokines secreted after pretreatment with these compounds.

As the NF-κB pathway was also identified as mediating RAGE overexpression after AGE-RAGE ligation, mast cells were incubated with 10 μM Glu-BSA for 3 h at 37°C and transcript levels for RAGE were assessed by PCR. No differences were found.
between the basal mRNA levels of RAGE in control cells compared with those in Glu-BSA treated cells (data not shown).

**Discussion**

To our knowledge, our data demonstrate for the first time that AGEs are capable of activating secretion of histamine from mast cells. Mast cells can be divided in two distinct classes: mucosal mast cells and serosal (or connective tissue) mast cells. Rat peritoneal mast cells belong to the serosal mast cell class. Serosal mast cells are mainly distributed in the sub-mucosa of the gastrointestinal tract, in the skin, in the brain and also in close proximity to blood vessels (Marshall, 2004). In particular, AGEs are known to accumulate in the vessel wall, especially in diabetes. Moreover, AGEs have been reported to accumulate in the brain during normal aging and also in several neurodegenerative disorders, including Alzheimer’s disease and amyotrophic lateral sclerosis (Yan *et al*., 2003; Ramasamy *et al*., 2005). Thus, serosal mast cells were tested for their reactivity to AGEs because of their critical location surrounding vessel walls and in the brain, where they are more likely to encounter AGEs compared with mucosal mast cells. Furthermore, serosal mast cells

---

**Figure 3**

Changes in emitted fluorescence (at 510 nm) from Fura-2-loaded mast cells excited alternately at 340 and 380 nm upon stimulation (arrow) with 10 μM Glu-BSA (A) and 10 μM Lact-BSA (B). Traces are representative of three independent experiments. Effect of pretreatment with BAPTA-AM (C) on exocytosis induced by Glu-BSA. Cells were pre-incubated with BAPTA-AM at the indicated concentrations (15 min, 37°C) and then stimulated for 10 min with 1 μM Glu-BSA. Data are mean ± SEM from three independent experiments. Effect of Glu-BSA on mast cell exocytosis in Ca²⁺-free HEPES buffer (D). Cells were stimulated for 10 min at 37°C with 10 μM Glu-BSA. Data are mean ± SEM from four independent experiments. Effects of caffeine (E) and 2-APB (F) on exocytosis induced by Glu-BSA. Cells were pre-incubated with the different agents at the indicated concentrations (15 min, 37°C) and then stimulated for 10 min with 10 μM (E) or 1 μM Glu-BSA (F) at 37°C. Data are mean ± SEM from three independent experiments.
are long-lived cells, unlike mucosal mast cells, and may therefore play a critical role in age-related inflammation.

We found that AGE-BSA activated mast cells with an apparent selectivity depending on the sugar attached to the BSA (Figure 1). Indeed, Glu-BSA, Gal-BSA and Man-BSA (all monosaccharide-containing compounds) induced mast cell exocytosis whereas Lact-BSA and Malt-BSA (which are disaccharide-containing compounds) were unable to activate mast cells. Physiological accumulation of such disaccharide-containing compounds may not occur because of enzymatic degradation occurring during assimilation. In any case, the concentrations of AGEs-BSA used here are in the same range as recently reported (Lappas et al., 2007; Nah et al., 2007; Rüster et al., 2008). The time course of exocytosis induced by 10 μM Glu-BSA was rapid, with a plateau response being reached within 10 to 20 s. These rapid kinetics indicate that the AGE-mediated pathway is different from the IgE/FceRI pathway for which stimulated exocytosis reaches a maximum only after a few minutes (Blank and Rivera, 2004). Note that the time course of histamine release induced by Glu-BSA is similar to that obtained after treatment of serosal mast cells with many other physiological secretagogues including substance P, bradykinin, neuropeptide Y or natural polyamines such as agmatine, spermine, spermidine (Mousli et al., 1989; Bueb et al., 1992; Ferry et al., 2002). We confirmed that histamine secretion induced by AGEs resulted from exocytosis and not lytic processes.

In addition to histamine, which alters vascular permeability, mast cells release other co-localized granule-associated mediators including heparin, chondroitin sulphate and proteases such as tryptase and chymase. These additionally released mediators take part in enhancing the effects of chemokines or cytokines and therefore contribute in the resultant remodelling of surrounding tissues and the recruitment of various effector cells (Marshall, 2004). Indeed, histamine and proteases promote for example the migration, maturation, differentiation and function of immune cells such as T cells, B cells, monocytes/macrophages, dendritic cells and granulocytes (Galli et al., 2008). Therefore, mast cells are of particular interest because they are very likely to contribute in a crucial manner in controlling the balance between pro- and anti-inflammatory signals that are known to be disturbed in cardiovascular diseases, neurodegeneration or cancers.

In the current study, we demonstrate for the first time that RAGE, a receptor for AGEs, is expressed in rat peritoneal mast cells (Figure 2). A recent report showed that RAGE was also expressed in other

**Figure 4**
Production of reactive oxygen species (ROS) induced by Glu-BSA (A). Cells were pre-incubated (5 min, 37°C) and then stimulated for 1 min with the indicated concentrations of Glu-BSA at 37°C. ROS were assessed using a chemiluminescent assay (RLU, relative light units). Data are mean ± SEM for four independent experiments. ***P < 0.001, significantly different compared with non-stimulated cells. Time course of ROS production induced by Glu-BSA (B). Cells were pre-incubated (5 min, 37°C) and then stimulated for the indicated times with 10 μM Glu-BSA at 37°C. Data are mean ± SEM for four independent experiments. ***P < 0.001, significantly different compared with time 0. Effect of pretreatment with anti-RAGE mAb on ROS production induced by Glu-BSA (C). Cells were pre-incubated with anti-RAGE mAb (100 μg·mL⁻¹, 1 h, 37°C) and then stimulated with 10 μM Glu-BSA for 1 min at 37°C. Data are mean ± SEM for four independent experiments. ***P < 0.001, significantly different compared with non-stimulated cells; ###P < 0.001, significantly different compared with the absence of blocking Ab.
mucosal types of mast cells, namely RBL-2H3 cells and BMMC (bone marrow-derived mast cells) and it was proposed that RAGE might mediate, in part, galectin-3-induced apoptosis in these cells (Suzuki et al., 2008). Our data indicated that RAGE mediated AGE-stimulated exocytosis of histamine from peri-
toneal mast cells because pretreatment with anti-
RAGE mAb and low molecular weight heparin, a
known antagonist having high affinity for RAGE
(Hanford et al., 2004; Myint et al. 2006; Liu et al.
2009), inhibited Glu-BSA-induced histamine secre-
tion. It should be noted that given the current lack
of other RAGE antagonists, use of function-blocking
Abs is widely used to verify the involvement of
RAGE in AGE-induced effects (for example: Yan et al.
1996; Origlia et al. 2008; Touré et al. 2008; Tanikawa
et al. 2009). We nevertheless attempted experiments
using siRNA-mediated knock-down of RAGE to

<table>
<thead>
<tr>
<th>Control</th>
<th>Glu-BSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>CINC-2</td>
<td>CINC-2</td>
</tr>
<tr>
<td>CINC-3</td>
<td>CINC-3</td>
</tr>
<tr>
<td>CNTF</td>
<td>CNTF</td>
</tr>
<tr>
<td>Fractalkine</td>
<td>Fractalkine</td>
</tr>
</tbody>
</table>

Table: Cytokine secretion from mast cells

<table>
<thead>
<tr>
<th>Pos</th>
<th>Pos</th>
<th>Neg</th>
<th>Neg</th>
<th>CINC-2</th>
<th>CINC-3</th>
<th>CNTF</th>
<th>Fractalkine</th>
</tr>
</thead>
<tbody>
<tr>
<td>GM-CSF</td>
<td>IFN-γ</td>
<td>IL-1β</td>
<td>IL-1β</td>
<td>IL-4</td>
<td>IL-6</td>
<td>IL-10</td>
<td>LIX</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>IFN-γ</td>
<td>IL-1α</td>
<td>IL-1β</td>
<td>IL-4</td>
<td>IL-6</td>
<td>IL-10</td>
<td>LIX</td>
</tr>
<tr>
<td>Leptin</td>
<td>MCP-1</td>
<td>MCP-3α</td>
<td>MIP-3α</td>
<td>TIMP-1</td>
<td>TNF-α</td>
<td>VEGF</td>
<td>Blank</td>
</tr>
<tr>
<td>Leptin</td>
<td>MCP-1</td>
<td>MCP-3α</td>
<td>MIP-3α</td>
<td>TIMP-1</td>
<td>TNF-α</td>
<td>VEGF</td>
<td>Blank</td>
</tr>
<tr>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Pos</td>
</tr>
<tr>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Blank</td>
<td>Pos</td>
</tr>
</tbody>
</table>

Figure 5
Effect of pretreatment with Glu-BSA (A), compound 48/80 (B) and peptide 4N1 (C) on cytokine secretion from mast cells. Cells were incubated with 10 μM Glu-BSA (A), 1 μg·mL⁻¹ 48/80 (B) or 100 μM 4N1 (C) for 6 h at 37°C or left untreated (control). Cytokines were assessed using an array assay with the cytokine-specific mAbs shown in the table (pos: positive control; neg: negative control). Blots were quantified following manufacturer’s instructions and are presented after normalization to values for positive controls for untreated and treated cells. The data are representative of two independent experiments.
confirm that RAGE is responsible for AGE-stimulated exocytosis. However, we found that freshly isolated, mature, rat peritoneal mast cells could not be maintained alone in culture for more than 2 days, unfortunately precluding siRNA-based experiments in these cells.

We found that downstream signalling by RAGE in mast cells involves $G$-proteins, as demonstrated by sensitivity to Pertussis toxin. Our results are in agreement with the few reports suggesting a possible coupling of RAGE with $G$-proteins: in human dendritic cells and in rat smooth muscle cells, activation of RAGE by amphoterin was inhibited by Pertussis toxin (Degryse et al. 2001; Yang et al. 2007). As mentioned in those studies, we cannot rule out that RAGE might contribute in targeting AGEs to a heptahelical $G$-protein-coupled receptor. Nevertheless, accumulating evidence indicates that heterotrimeric $G$-proteins can also be activated by some non-heptahelical receptors. For example, this property has been attributed to some transmembrane proteins having or not cytosolic kinase activity, and also for some receptors belonging to the class of glycosylphosphatidylinositol (GPI)-anchored proteins (Landry et al. 2006).

Stimulation of histamine secretion by AGEs also requires an increase in intracellular $\text{Ca}^{2+}$ released from internal stores and not influx, from extracellular sources, as Glu-BSA induced histamine occurred in the absence of extracellular $\text{Ca}^{2+}$ (Figure 3). This is in agreement with the well-described signalling pathway leading to mast cell exocytosis that involves $G$-proteins and intracellular $\text{Ca}^{2+}$ increases (Nakamura and Ui, 1985; Mousli et al. 1989; 1992; Bueb et al. 1992; Ferry et al. 2001). However, our data represent the first indication that RAGE may also act via this signalling pathway.

We showed that AGEs induced a dose-dependent increase in ROS production in mast cells with a maximal effect being obtained within 30 s (Figure 4). Our data indicate that RAGE mediates AGE-stimulated ROS production from peritoneal mast cells because pretreatment with anti-RAGE mAb inhibited Glu-BSA-induced ROS production. A large body of evidence suggests that ROS generation, in part via the activation of NADPH oxidase, is a consequence of AGE-RAGE interactions (Yan et al. 1994; Lander et al. 1997; Wautier et al. 2001). Recent studies have underscored the notion that $\text{Ca}^{2+}$ and ROS signalling systems are intimately interrelated. Indeed, a number of ROS-generating and anti-oxidant systems, such as the cell-surface NADPH oxidase, have been shown to be $\text{Ca}^{2+}$-dependent. Cell surface NADPH-oxidases, with rapid kinetics of activation and inactivation, are the most important multienzyme complexes in receptor-mediated signalling cascades that result in the generation of ROS (Brookes et al. 2004). We propose that intracellular $\text{Ca}^{2+}$ increases in mast cells also leads to ROS generation. In support, it has been shown that rat peritoneal mast cells produce ROS in response to the $\text{Ca}^{2+}$ ionophore A23187 (Niu et al. 1996) and that upon degranulation induced via the IgE/antigen pathway, both human and rodent mast cells generate ROS. Both IgE-mediated release of 5-HT and generation of ROS were inhibited by diphenyleneiodonium, a flavon-zyme inhibitor (Swindle et al. 2004). Furthermore, compounds known to induce exocytosis in mast cells such as nerve growth factor (NGF), compound 48/80 and substance P have also been found to cause ROS generation in rat peritoneal mast cells (Brooks et al. 1999). These data are consistent with ROS generation being tightly related to intracellular $\text{Ca}^{2+}$ increase and exocytosis in mast cells. It can also be suggested that ROS production is tightly related to increased formation of AGEs. For example, in endothelial cells, glucose-induced increases in mitochondrial superoxide have been described to be a key factor in generation of AGEs (Nishikawa et al. 2000). The formation of AGEs stimulated by oxidative stress and ROS generation, inflammatory stimuli, physical injury and hyperglycaemia is believed to be a key first step in broad array of injury settings (Ramasamy et al. 2005). Therefore, AGEs may participate in a vicious cycle whereby ROS generation leads to amplified generation of AGEs and activation of RAGE, particularly in inflammation and aging. In agreement, during aging, naturally occurring AGEs accumulate, oxidative damage increases and antioxidant levels decrease (see Dröge and Schipper, 2007). These age-related dysfunctions, together with the low-grade chronic inflammation observed in aging people, are consistent with inflammatory cells, in particular mast cells, being key actors in controlling ROS production, enhanced generation of AGEs and RAGE activation.

Our data show that RAGE-mediated activation of mast cells results in specific short time-course responses like histamine release and ROS production. Indeed, as reviewed recently, differential release of mast cell mediators can occur depending on the stimulus (Galli et al. 2005; Theoharides et al. 2007). Thus, histamine release is not necessarily accompanied by de novo synthesis of cytokines and their subsequent secretion. In our case, stimulation of mast cells with AGE-BSA rapidly leads to histamine release and production of ROS. Responses occurring on a longer time scale (like synthesis and secretion of cytokines or changes in RAGE levels) were absent (Figure 5).
We also show that compound 48/80, a classical mast cell activator, and peptide 4N1, a CD47 receptor agonist, do not trigger cytokine release from rat peritoneal mast cells (Figure 5). However, both 48/80 and CD47-mediated activation of mast cells result in histamine release and ROS production (Brooks et al. 1999; Sick et al. 2009). Note that 48/80 and CD47-mediated signalling pathways share several common features with AGE-mediated mast cell activation: degranulation being essentially complete within 20 s, exclusive release of preformed mediators and lack of dependence on extracellular Ca\(^{2+}\). These are hallmarks of the so-called IgE-independent mast cell activation pathway (see Gies et al. 1993; Metcalfe et al. 1997; Ferry et al. 2002). In contrast, mast cells stimulated by lipopolysaccharide (LPS) or IgE/FcεRI interaction release both preformed and newly formed mediators (Leal-Berumen et al. 1994). Indeed, both LPS and IgE trigger histamine release and secretion of interleukin (IL)-6. Interestingly, IL-6 secretion induced by LPS or IgE is totally inhibited in the absence of extracellular Ca\(^{2+}\). On the other hand, in response to the calcium ionophore A23187, mast cells release histamine but not IL-6. Furthermore, FcεRI aggregation requires extracellular Ca\(^{2+}\) as well as the activation of several signalling kinases, including phosphatidylinositol 3-kinase (PI3K), extracellular signal regulated kinase (ERK), protein kinase C (PKC), c-Jun N terminal kinase (JNK), and of NF-κB. By contrast, IL-6 secretion induced by IL-1 does not require extracellular Ca\(^{2+}\) but involves p38 MAPK, NF-κB and PKC\(_\theta\) activation (Theoharides et al. 2007). Overall, as suggested previously (Galli et al. 2005; Theoharides et al. 2007), mast cells are tunable effectors with individual activation pathways and associated downstream signalling differentially conditioning secretory responses.

In conclusion, we show that AGES rapidly induced exocytosis of histamine and production of ROS in mast cells. These actions of AGES in mast cells were mediated by RAGE and involved G\(_\alpha\)-proteins (Figure 6). We propose that mast cells may contribute to the regulation of the amounts of AGES via feedback mechanisms involving ROS generation. Therefore, mast cells may well play a key role in establishing and maintaining the chronic, low-grade inflammatory state that characterizes aging and pathologies like cancer, neurodegeneration and cardiovascular diseases.

Acknowledgements This work was in part supported by the CNRS and the Ligue Contre le Cancer (grant to JPG, from the Comité du Haut-Rhin et du Bas-Rhin). ES was recipient of a Fellowship from the Ministère de la Recherche.

Conflict of interest

The authors state no conflict of interest.

References


Brooks AC, Whelan CJ, Purcell WM (1999). Reactive oxygen species generation and histamine release by

Figure 6

Representation of a postulated positive-feedback loop whereby ROS generation induced by AGE-RAGE interaction leads to increased formation of AGES. Together with AGE-stimulated histamine release, increased ROS production would contribute to the establishment and maintenance of the chronic inflammatory state. AGES, advanced glycation endproducts; RAGE, receptor for AGES; ROS, reactive oxygen species.


